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Abstract
In this study, we have identified a unique mechanism in which human cytomegalovirus (HCMV) protein pUL79 acts as an
elongation factor to direct cellular RNA polymerase II for viral transcription during late times of infection. We and others
previously reported that pUL79 and its homologues are required for viral transcript accumulation after viral DNA synthesis.
We hypothesized that pUL79 represented a unique mechanism to regulate viral transcription at late times during HCMV
infection. To test this hypothesis, we analyzed the proteome associated with pUL79 during virus infection by mass
spectrometry. We identified both cellular transcriptional factors, including multiple RNA polymerase II (RNAP II) subunits,
and novel viral transactivators, including pUL87 and pUL95, as protein binding partners of pUL79. Co-immunoprecipitation
(co-IP) followed by immunoblot analysis confirmed the pUL79-RNAP II interaction, and this interaction was independent of
any other viral proteins. Using a recombinant HCMV virus where pUL79 protein is conditionally regulated by a protein
destabilization domain ddFKBP, we showed that this interaction did not alter the total levels of RNAP II or its recruitment to
viral late promoters. Furthermore, pUL79 did not alter the phosphorylation profiles of the RNAP II C-terminal domain, which
was critical for transcriptional regulation. Rather, a nuclear run-on assay indicated that, in the absence of pUL79, RNAP II
failed to elongate and stalled on the viral DNA. pUL79-dependent RNAP II elongation was required for transcription from all
three kinetic classes of viral genes (i.e. immediate-early, early, and late) at late times during virus infection. In contrast, host
gene transcription during HCMV infection was independent of pUL79. In summary, we have identified a novel viral
mechanism by which pUL79, and potentially other viral factors, regulates the rate of RNAP II transcription machinery on viral
transcription during late stages of HCMV infection.
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Introduction
HCMV is a prototypical beta-herpesvirus and a ubiquitous
pathogen in the human population. Upon primary infection,
HCMV establishes a lifelong persistent and latent/recurrent
infection in a host [1]. Even though HCMV infection is usually
asymptomatic, it acts as an opportunistic pathogen and is a major
cause of morbidity and mortality in immunocompromised
individuals, including transplant recipients and AIDS/HIV
patients [2]. Importantly, HCMV is the leading infectious cause
of birth defects in newborns [3]. Furthermore, there is evidence for
HCMV to act as a risk factor in the development of vascular
diseases, such as atherosclerosis, transplant vascular sclerosis, and
coronary restenosis after angioplasty surgery [4–10]. Finally,
HCMV has also been suggested to be relevant to multiple forms
of human cancers, where it may have a potential contribution to
oncogenic transformation, onco-modulation, and tumor cell
immune evasion [11–14].
During lytic infection, HCMV genes are expressed in a highly
ordered temporal cascade (reviewed in [15–18]). Viral transcripts
accumulate with three kinetic classes, namely immediate-early,
early, and late. The HCMV major IE (MIE) genes UL123 (IE1)
and UL122 (IE2) play critical roles in predisposing the cellular
environment to infection and also act as transactivators to induce
early gene transcription. Many early genes encode proteins
required for viral DNA synthesis [19–21]. The transcript
accumulation of early genes is independent of viral DNA synthesis;
however, the continued accumulation of a subset of genes (i.e.,
early-late) is enhanced by the onset of viral DNA synthesis [22].
Following viral DNA replication, late viral genes, which mainly
encode structural proteins, start to transcribe and ultimately lead
to the assembly and release of infectious particles. Previous studies
have shown that the activation of both beta- and gamma-
herpesvirus late gene promoters is dependent on the origin of viral
DNA synthesis (OriLyt) in cis [23–25]. This further supports the
notion that late gene transcription is tightly coupled to viral DNA
synthesis. However, whether viral late gene expression is subjected
to additional viral regulation remains poorly defined.
In many DNA viruses, viral gene expression during productive
infection is also temporally regulated and can be divided into early
and late phases separated by viral genome replication. However,
the mechanisms of late gene expression are diverse. Simian virus
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40 (SV40) requires viral DNA replication in trans to relieve the
repression of viral late promoters [26,27], and the viral large T
antigen also plays a critical role to activate the late promoters
[28,29]. Viral late gene expression during papillomavirus
infection is tightly associated with keratinocyte differentiation
and mediated in part by alternative mRNA splicing [30]. For
adenoviruses, activation of late gene expression requires both cis
elements of viral DNA replication [31,32] and trans acting
factors to titrate an inhibitory factor during viral DNA synthesis
[33]. For herpesviruses, viral late gene expression has been
studied extensively with herpes simplex virus (HSV). In HSV,
viral DNA replication is required in cis for activity of late
promoters [34,35]. HSV proteins, including ICP4, ICP8, and
ICP27, facilitate the assembly of transcription preinitiation
complexes [36,37], and are required for efficient expression of
late genes by interacting with the general transcription
machinery [38–40]. However, the regulatory activities of these
viral proteins in late gene expression are not well conserved in
beta- and gamma-herpesviruses.
Recently, we and others have demonstrated that HCMV
encodes five essential proteins, UL79, UL87, UL91, UL92, and
UL95, which are required for the expression of viral late genes
after viral DNA synthesis [41–43]. Murine cytomegalovirus
(MCMV) M79 and M92, homologs of HCMV UL79 and
UL92, respectively, are also required for late gene expression
[44,45]. Homologs of UL79, UL87, UL91, UL92, and UL95 are
found in murine gammaherpesvirus 68 (MHV-68) (ORF18,
ORF24, ORF30, ORF31, and ORF34, respectively), which have
been shown to have similar functions [46–49]. Epstein-Barr virus
(EBV) BcRF1, a UL87 homolog, is a novel viral TATA-box
binding protein with greater specificity for a non-classical TATA-
box sequence [50,51]. Intriguingly, these factors are conserved
only in beta- and gamma-herpesviruses and have no known
homologues in herpes simplex virus (HSV) [18,41], suggesting a
unique viral regulatory mechanism shared by these two herpesviral
subfamilies. However, the underlying mechanisms of how these
viral factors regulate late gene expression are incompletely
understood.
During cytomegalovirus infection, viral genes are transcribed by
cellular RNA polymerase II (RNAP II). Its largest subunit Rpb1
has a carboxy terminal domain (CTD) containing 52 repeats of a
heptapeptide (Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7) [52]. The
CTD acts as a scaffold to interact with other transcription factors
and coordinate transcription with other processes, such as mRNA
maturation and chromatin modification [53,54]. This activity is
tightly regulated by the phosphorylation status of the CTD
[55,56]. Unphosphorylated RNAP II is recruited to preinitiation
complexes (PIC) [57]. Once bound to a promoter, CTD Ser5 is
phosphorylated by cdk7 to release RNAP II from the PIC [58] and
also promote the recruitment of capping/splicing factors and
histone modification complexes [53]. RNAP II then proceeds to
intrinsic pausing sites where it is halted by negative elongation
factors (NELFs). The onset of productive elongation requires the
positive transcription elongation factor P-TEFb composed of cdk9
and cyclin T, which phosphorylates CTD Ser2 [59]. At the 39 end
of the coding region, phosphatases Ssu72 and Fcp1 dephosphor-
ylate the CTD. RNAP II dissociates from the DNA template and
is recycled as an unphosphorylated, initiation-competent form for
another round of transcription [60,61].
HCMV utilizes RNAP II and the accompanying host machin-
ery for transcription of viral genes. During early times of viral
infection, RNAP II and other transcription machinery are
recruited to early replication sites to drive viral IE and early gene
expression [62]. The protein levels of RNAP II, including hyper-
phosphorylated forms, increase as infection progresses [62,63].
Treatment of infected cells with cdk inhibitors inhibits viral gene
expression as well as viral replication [64]. During late stages of
viral infection, cdk kinase and RNAP II-associated transcriptional
machinery proteins continue to accumulate and relocate into the
peri-replication center [65]. However, how RNAP II transcription
machinery remains active on viral loci during late infection
requires further investigation.
In this study, we dissected the mechanism of HCMV late gene
expression by investigating the proteins that are associated with
late transcription regulator pUL79 during HCMV infection. We
found that pUL79 interacted with a panel of viral and host
proteins, including RNAP II, other novel late transcription
regulators pUL87 and pUL95, as well as components of the viral
DNA replication complex. We delineated the pUL79-RNAP II
interaction and found that pUL79 bound to RNAP II in the
nucleus independent of additional viral factors. Mechanistically,
pUL79 did not alter RNAP II protein levels or the phosphory-
lation profile of its CTD. Instead, in the absence of pUL79, RNAP
II stalled on viral DNA loci, including those of viral immediate-
early, early, and late genes, but not those of host genes, during late
times of infection. This resulted in a significantly diminished
elongation rate of RNAP II-driven transcription on viral loci. We
conclude that during late times of infection HCMV induces the
formation of unique transcriptional machinery in which pUL79
acts as an elongation factor to specifically drive RNAP II-mediated
transcription on the viral genome.
Results
Identification of pUL79-interacting proteins
To investigate proteins associated with pUL79, we first
generated a recombinant HCMV in which the UL79 coding
sequence was tagged with the 36FLAG sequence (ADflagUL79)
so that protein complexes containing pUL79 in infected cell lysate
could be isolated by immunoprecipitation (IP) with an anti-FLAG
antibody (Fig. 1A). Both growth and protein expression profile
(Figs. 1B–1C) of ADflagUL79 was indistinguishable from those of
Author Summary
In this study, we report a novel mechanism used by human
cytomegalovirus (HCMV) to regulate the elongation rate of
RNA polymerase II (RNAP II) to facilitate viral transcription
during late stages of infection. Recently, we and others
have identified several viral factors that regulate gene
expression during late infection. These factors are func-
tionally conserved among beta- and gamma- herpesvirus-
es, suggesting a unique transcriptional regulation shared
by viruses of these two subfamilies. However, the
mechanism remains elusive. Here we show that HCMV
pUL79, one of these factors, interacts with RNAP II as well
as other viral factors involved in late gene expression. We
have started to elucidate the nature of the pUL79-RNAP II
interaction, finding that pUL79 does not alter the protein
levels of RNAP II or its recruitment to viral promoters.
However, during late times of infection, pUL79 helps RNAP
II efficiently elongate along the viral DNA template to
transcribe HCMV genes. Host genes are not regulated by
this pUL79-mediated mechanism. Therefore, our study
discovers a previously uncharacterized mechanism where
RNAP II activity is modulated by viral factor pUL79, and
potentially other viral factors as well, for coordinated viral
transcription.
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wildtype AD169 strain (ADwt) in human foreskin fibroblasts cells
(HFFs). These results indicate that the addition of 36FLAG tag to
the N-terminus of the UL79 coding sequence does not compro-
mise the function of pUL79.
To identify proteins that interacted with FLAG-pUL79, lysates
from HFF cells infected with virus ADflagUL79 or ADwt
(negative control) were collected at 72 hours post infection (hpi)
and immunoprecipitated with the anti-FLAG antibody. Immuno-
precipitated proteins were resolved by SDS-PAGE and visualized
by silver staining (Fig. 1D). Protein bands unique to ADflagUL79
were extracted and their identities were determined by mass
spectrometry. For the negative control, we also extracted gel bands
from the ADwt sample with migrating positions corresponding to
those of ADflagUL79-specific protein bands as negative controls
for mass-spectrometry analysis. The full set of proteins that were
identified by this approach and unique to ADflagUL79 is listed in
Table 1.
These pUL79-interacting proteins could be categorized into
several functional groups. Most notably, four out of twelve core
subunits of human RNA polymerase II (RNAP II), namely Rpb1,
Rpb2, Rpb3, and Rpb5, were identified (Table 1). Rpb1 is the
largest subunit of RNAP II and its C-terminal domain (CTD) plays
a critical role in transcription regulation by interacting with
various transcriptional factors. Second, several viral proteins that
are conserved among beta- and gamma- herpesviruses, including
pUL87, pUL95, pUL49, and pUL92, were found in the pUL79-
protein complexes. pUL87 and pUL95 (shown in Table 1),
together with pUL79, are required for viral late gene expression
and are reported to be recruited to the viral pre-replication
complexes [42,43]. pUL92, another HCMV protein required for
viral late gene expression, was also identified in this mass
spectrometry analysis as a pUL79-interacting protein and has
been reported as such in a separate study [44]. These data
together suggest that pUL79 interacts with other viral regulatory
proteins involved in late gene expression during HCMV infection.
Third, proteins involved in viral DNA synthesis or shown to be
associated with viral lytic origin of replication (OriLyt) [66],
including pUL44, pIRS1, and pUL112/113, were also found in
pUL79 protein complexes. Copurification of pUL79 and viral
DNA replication factors suggests that pUL79 may have a role in
coordinating viral DNA synthesis and late gene expression.
Finally, several cellular proteins involved in protein translation,
such as ribosomal protein subunits and elongation factor 1-alpha1,
were co-purified with pUL79.
In this study, we focused on the interaction between pUL79 and
RNAP II subunits. As RNAP II transcribes viral genes during
infection, we hypothesized that pUL79 interacts with RNAP II to
modify and promote its activity for viral transcription during late
stages of infection.
pUL79 interacts with the RNAP II complex
To further investigate the association of the RNAP II complex
with pUL79, we first validated this interaction by immunoprecip-
itation analysis. HFFs were infected with either ADflagUL79 or
ADwt (negative control), cell lysates were collected at 72 hpi, and
proteins were immunoprecipitated by using antibodies against
RNAP II or FLAG, followed by immunoblot analysis (Fig. 2). For
the cells infected with ADflagUL79, two RNAP II subunits, Rpb1
and Rpb2, were co-immunoprecipitated with FLAG-pUL79 but
were not co-immunoprecipitated from ADwt-infected samples
(Fig. 2A). In a reciprocal experiment, an anti-Rpb1 antibody co-
immunoprecipitated not only the RNAP II complex (indicated by
Rpb1 and Rpb2) in both ADflagUL79- and ADwt- infected
samples, but also FLAG-pUL79 in ADflagUL79-infected samples
(Fig. 2B). Taken together, these results indicate that pUL79 is
associated with the RNAP II complex during viral infection.
The RNAP II complex binds to both DNA and RNA
fragments. It is possible that the observed interaction of pUL79
with RNAP II is indirect, and is instead the result of the association
of both proteins with the same DNA or RNA fragment. To
determine if nucleic acids are required for the pUL79-RNAP II
interaction, cell lysates were treated with a nonspecific nuclease
(Benzonase) prior to immunoprecipitation [67]. Benzonase treat-
ment was effective, reducing RNA/DNA to undetectable levels in
ethidium bromide-stained agarose gel electrophoresis analysis
(Fig. 2A and Fig. 2B). In the presence of nuclease, pUL79, Rpb1,
and Rpb2 remained co-immunoprecipitated in ADflagUL79-
infected lysates (Fig. 2A and 2B). Taken together, these results
indicate that pUL79 and RNAP II associate with one another, and
that this association is not mediated by nucleic acids.
We then sought to determine whether the pUL79-RNAP II
interaction could form independent of additional viral factors. To
achieve this, we transfected HEK-293T cells with a plasmid
expressing HA-tagged pUL79 or an empty vector plasmid. pUL79
contains a PY-nuclear localization signal directing it into the
nucleus [68] and is located in viral replication compartments
during infection [42,43]. Therefore, we extracted nuclear lysates of
transfected cells, and performed co-immunoprecipitation analysis
to examine the pUL79-RNAP II interaction using either an anti-
HA antibody or anti-Rpb1 antibody in the presence of nuclease.
As anticipated, HA-pUL79 was present in the nuclear extracts
(Fig. 2C and 2D). Anti-HA antibody immunoprecipitated HA-
pUL79 together with Rpb1, particularly the Rpb1 CTD
phosphorylated at Serine 2 (pSer2-CTD) (Fig. 2C). As pSer2-
CTD is a marker of RNAP II undergoing transcriptional
elongation, this result suggests that pUL79 may interact with
RNAP II during the transcription cycle to modulate its elongation.
Reciprocal co-immunoprecipitation using an anti-Rpb1 antibody
further confirmed the association of RNAP II with pUL79
(Fig. 2D). Together, these results indicate that pUL79 can interact
with RNAP II independent of other viral factors. The presence of
pSer2-CTD in the pUL79-RNAP II complex also suggests that
pUL79 may regulate the elongation activity of RNAP II.
pUL79 does not alter protein accumulations of RNAP II
A previous study found that HCMV promotes the accumulation
of RNAP II at late times during infection [63]. Various isoforms of
phosphorylated RNAP II, including pSer2-CTD and pSer5-CTD
(i.e. CTD phosphorylated at Serine 5, a hallmark of successful
transcription initiation) also accumulate at these late times
[62,63,69]. However, the mechanism of how HCMV regulates
these RNAP II-mediated transcriptional events is not clear.
To determine whether the pUL79-RNAP II association can
stabilize the RNAP II complex to increase its protein levels, we
measured RNAP II protein accumulation during HCMV infection
in the presence or absence of pUL79 protein. We have previously
constructed a recombinant HCMV virus ADddUL79 in which the
UL79 coding sequence was tagged with the highly unstable
ddFKBP domain [42]. This allowed us to abrogate pUL79
function by targeting it for rapid degradation, or maintain its
function by stabilizing the protein with the synthetic ligand Shield-
1 (Shld1) [42]. Here, we infected HFF cells with ADddUL79 in the
presence or absence of Shld1, and analyzed infected cell lysates by
immunoblotting at various times post infection. As anticipated, in
the presence of Shld1, ddFKBP-pUL79 was detected at 72 hpi
from total cell lysates (Fig. 3) or nuclear extracts (Fig. S1) using the
antibody recognizing the ddFKBP epitope. In the absence of
Shld1, ddFKBP-pUL79 was markedly reduced and barely visible
CMV pUL79 Is a Viral Elongation Factor of RNAP II
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Figure 1. Identification of pUL79 interacting proteins. (A) Schematic diagram for creating pADflagUL79, the recombinant HCMV BAC clone
used to produce virus ADflagUL79. A cassette that contained a 36FLAG tag followed by the FRT-bracketed GalK/kanamycin dual selection marker
was amplified by PCR and recombined into the wildtype HCMV BAC clone (pADwt) at the 59 terminus of the UL79 coding sequence. The selection
marker was then removed by Flp/FRT recombination. The final clone, pADflagUL79, carried the UL79 coding sequence tagged at its 59 terminus with
36FLAG. (B) Single step viral growth analysis. HFF cells were infected with HCMV recombinant virus ADflagUL79 (derived from pADflagUL79) or ADwt
(derived from pADwt) at an MOI of 3. Infected culture supernatants were collected at indicated days post infection and virus titers were determined
by TCID50 assay. The mean virus titers were derived from two independent experiments and two technical replicates. Standard deviations are
presented. The detection limit is indicated by the dashed line. (C) Viral protein expression profile. HFFs were infected as described in (B), and
harvested at indicated times post infection. Accumulations of host and viral proteins were determined by immunoblot analysis. FLAG-tagged pUL79
was detected by an anti-FLAG antibody. Actin was used as a loading control. Representative results from three independent experiments are shown.
(D) Polyacrylamide gel electrophoresis to resolve pUL79 protein complexes. HFFs were infected as described in (B), and at 72 hpi, cell lysates were
prepared for immunoprecipitation using an anti-FLAG antibody. Immunoprecipitated proteins were resolved on a gradient polyacrylamide gel and
silver stained. Protein bands containing RNAP II subunits identified by mass spectrometry are indicated. Molecular size markers (in kilodaltons) are
shown.
doi:10.1371/journal.ppat.1004350.g001
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only after prolonged exposure by immunoblot analysis. To
confirm this regulation of pUL79 activity, we also examined
expression profiles of representative viral immediate-early (IE1),
early (pUL44), and late (pp71) proteins. In the presence of pUL79,
all three classes of viral proteins were accumulated with the
expected kinetics (Fig. 3). In the absence of pUL79, immediate-
early and early proteins accumulated normally but the accumu-
lation of the late protein was dramatically reduced (Fig. 3). These
results were consistent with the previous study [42], and validated
the effectiveness of Shld1-mediated regulation of pUL79 activity in
this study. Importantly, the protein levels of Rbp2 and Rpb1 (both
total Rpb1 and various CTD-phosphor isoforms) increased as
expected when infection progressed [62,63], but the accumula-
tions were independent of the presence or absence of pUL79
(Fig. 3). Together, these results indicate that total RNAP II as well
as its CTD modified forms accumulate during viral infection in a
pUL79-independent manner.
pUL79 alters RNAP II occupancy at viral loci
A previous study showed that MHV-68 ORF30 and ORF34,
homologues of HCMV UL91 and UL95, respectively, are
required for the recruitment of RNAP II to the viral late
Table 1. pUL79 protein partners identified by mass spectrometry.
Protein ID Description Size (kDa) Expectationa Peptide count
HCMV transactivators
B8YEB2 pUL87 104.7 0 44
B8YEB9 pUL95 57.2 9.4610E-37 26
A8T7F6 pUL79 33.8 1.5610E-40 12
HCMV DNA synthesis
Q69214 UL112/113 (pp34) 28.3 2.7610E-14 7
D2K4M1 UL112 (pp84) 70.2 3.2610E-15 6
D2K5E9 pUL44 (DNA pol. processivity factor) 46.2 8.0610E-6 2
C8CFZ3 IRS1 (tegument protein) 91.7 9.6610E-3 1
Other HCMV proteins
D2K3R0 pUL104 (capsid portal protein) 78.4 2.5610E-35 10
D2K4X8 pUL85 (capsid triplex subunit) 34.5 2.8610E-16 7
D2K4H6 pUL150 (nuclear egress protein) 43.1 1.1610E-05 2
Q1KQ04 pUL49 63.8 0.01 1
Cellular RNA polymerase II
RPB2_Human Subunit Rpb2 133.8 8.8610E-101 29
RPB1_Human Subunit Rpb1 217 2.6610E-81 27
RPB3_Human Subunit Rpb3 31.4 1.1610E-20 6
RPB5_Human Subunit Rpb5 24.5 6.8610E-07 2
Ribosome biogenesis
RL7A_Human 60S ribosomal protein L7a 29.9 4.6610E-07 3
RL21_Human 60S ribosomal protein L21a 18.5 2.1610E-11 3
RS2_Human 40S ribosomal protein RPS2 31.3 6.7610E-05 3
RS3A_Human 40S ribosomal protein RPS3a 29.9 4.4610E-04 3
RL23_Human 60S ribosomal protein RPL23 14.8 3.9610E-04 2
RL23A_Human 60S ribosomal protein RPL23a 17.6 3.6610E-04 1
RL24_Human 60S ribosomal protein L24 17.7 8.8610E-01 1
RS26L_Human 40S ribosomal protein S26-like 1 12.9 9.8610E-03 1
RS27A_Human Ubiquitin-40S ribosomal protein S27a 17.9 0.23 1
Other cellular proteins
ACTB_Human Actin, cytoplasmic 1 41.9 4.6610E-51 15
ACTN1_Human Alpha-actinin-1 102.9 8.4610E-10 3
EF1A1_Human Elongation factor 1-alpha 1 50.1 4.8610E-3 3
ANXA5_Human Annexin A5 35.9 9.7610E-3 3
H2A1B_Human Histone H2A type 1-B/E 14.12 0.15 3
RECQ4_Human ATP-dependent DNA helicase Q4 132.9 0.25 1
aExpectation value for peptide match (i.e. the number of times expected to obtain an equal or higher score, purely by chance). A lower value indicates a higher
likelihood of the interaction.
doi:10.1371/journal.ppat.1004350.t001
CMV pUL79 Is a Viral Elongation Factor of RNAP II
PLOS Pathogens | www.plospathogens.org 5 August 2014 | Volume 10 | Issue 8 | e1004350
promoters [48]. Like ORF30 and ORF34, both UL91 and UL95
were reported to be essential for late gene expression [41,43]. In
this study, we identified pUL95 as a protein partner of pUL79
(Table 1). Therefore, we hypothesized that pUL79 forms a
complex with pUL95 and other binding partners to recruit RNAP
II and promote assembly of the transcription initiation complex at
viral late promoters.
To test this, we determined the occupancy of RNAP II on viral
late promoters with or without pUL79 during infection using a
chromatin immunoprecipitation (ChIP) assay. HFFs were infected
with ADddUL79 in the presence or absence of Shld1 and
chromatin fractions from infected cells were collected at 72 hpi
and analyzed by ChIP assay using a rabbit anti-RNAP II
antibody. The amounts of input and output (immunoprecipitated)
DNA were measured by quantitative real-time PCR (qPCR)
analysis using primers specific to the promoter or transcript
regions of viral genes or the cellular housekeeping gene GAPDH
(Table S2). The localizations of qPCR primers and sizes of qPCR
products are diagramed in Fig. 4A. The qPCR results were
presented as relative output-to-input ratios to account for the
percentages of host/viral genomes occupied by RNAP II during
viral infection (Fig. 4B). The levels of viral and cellular DNA
immunoprecipitated by Rbp1 antibody were readily detectable
whereas DNA immunoprecipitated by control IgG was minimal,
indicating the specific binding of Rbp1 to the DNA sequences
detected in this assay. However, to our surprise, the occupancy
of Rpb1 at the promoter or transcript regions of viral genes was
not reduced in the absence of pUL79, suggesting that pUL79 is
not required for RNAP II recruitment to viral promoters
(Fig. 4B). Instead, without pUL79, Rpb1 levels on viral DNA
were ,2–2.5 fold higher than those with pUL79. Importantly,
during late times of infection (72 hpi), elevated Rpb1 accumu-
lation occurred not only on the loci of viral late genes (UL32
and UL75), it also occurred on those of viral immediate-early
genes (MIE) and early genes (UL54) (Fig. 4B). Moreover, this
increased association of RNAP II with viral DNA occurred at
both promoter regions and transcript regions. By comparison,
Rpb1 occupancy on the host gene GAPDH was not altered by
pUL79.
If pUL79 modulates RNAP II occupancy on viral loci, we
would then expect that pUL79 is associated with RNAP II on viral
loci. To test this hypothesis, we determined the occupancy of
pUL79 on either viral or host loci during infection. HFFs were
infected with ADflagUL79 or ADwt viruses and chromatin
fractions from infected cells were collected at 72 hpi and analyzed
by ChIP assay using either an anti-FLAG antibody, which
recognizes the 36 FLAG-tagged UL79 protein, or a control IgG
antibody. The amounts of input and output (immunoprecipitated)
DNA were measured by qPCR analysis using primers identical to
those in Fig. 4B. Viral DNA immunoprecipitated by the FLAG
antibody from ADflagUL79 samples was readily detectable
whereas DNA immunoprecipitated by control IgG was minimal,
indicating the specific binding of the FLAG tagged pUL79 to the
DNA sequences detected in this assay (Figs. 4C and S3).
Although certain amounts of background DNA were also
immunoprecipitated by the FLAG antibody from ADwt
samples, the amounts of viral DNA immunoprecipitated from
ADflagUL79 samples were generally higher, as determined by
ChIP-qPCR. This supports the hypothesis that pUL79 occupies
viral loci at late times of viral infection. Finally, amounts of
cellular DNA (i.e. GAPDH) immunoprecipitated from both
ADflagUL79 and ADwt samples were minimal and indistin-
guishable, suggesting that pUL79 is not associated with the host
genome during viral infection (Fig. 4C).
Taken together, these results indicate that pUL79 regulates the
occupancy of RNAP II on viral loci, but not its recruitment to viral
promoters, during late times of viral infection.
pUL79 does not alter a particular phosphorylated form of
the RNAP II CTD
Next, we wanted to determine how the observed dysregulated
elevation in the occupancy of RNAP II on viral DNA when
pUL79 was abrogated contributed to its diminished ability to
transcribe viral genes. Specifically, we wanted to determine which
stage of the RNAP II transcription cycle (i.e. initiation, elongation,
or termination) was altered by pUL79 by performing ChIP
analysis using antibodies that recognize various forms of RNAP II
CTD modifications. In a transcription cycle, Ser5 of RNAP II
CTD is rapidly phosphorylated (pSer5-CTD) to facilitate the
dissociation of RNAP II from the promoter and recruitment of
RNA capping and splicing factors. After that, pSer5 CTD levels
decrease with a concomitant increase in Ser2 phosphorylation
(pSer2-CTD) to facilitate efficient transcription elongation. At
72 hpi, we found that both pSer5-CTD and pSer2-CTD levels
significantly increased on viral loci in the absence of pUL79
compared to those in the presence of pUL79 (Fig. 5A). However,
the increase of unphosphorlyated CTDs on viral loci also
paralleled that of phosphorylated CTD (Fig. 5A). Therefore
pUL79 abrogation appeared to elevate all forms of CTD
modifications tested at viral loci.
To more specifically determine whether the elevated accumu-
lation of RNAP II on viral DNA arose from a specific CTD
modification in the absence of pUL79, we normalized the ChIP
occupancy values of pSer5-CTD, pSer2-CTD, and unphosphory-
lated CTD to that of total RNAP II. Occupancies of various CTD
modifications were proportional to that of total RNAP II, and we
found no evidence for the preferential occupancy of a particular
CTD modification on any viral locus examined (Fig. 5B).
Therefore, elevated RNAP II occupancy in the absence of
pUL79 was unlikely to be due to the dysregulation of CTD
phosphorylation. Consistently, protein levels of CTD kinases
(Cyclin T1 and CDK9) and CTD phospho-isoforms (pSer2-CTD,
pSer5-CTD, pSer5/pSer2-CTD) were not altered by the presence
or absence of pUL79 (Fig. 3). These results together indicate that
pUL79 is not involved in phosphorylation of RNAP II CTD, and
suggest that without pUL79, RNAP II simply stalls during the
transcription cycle, resulting in its elevated accumulation at viral
loci.
pUL79 alters the rate of transcriptional elongation at viral
loci
Based on the above results, we hypothesized that pUL79 was
required for efficient elongation of RNAP II-driven transcrip-
tion at viral loci. To test this, we determined RNAP II
elongation activity using a nuclear run-on (NRO) assay. The
NRO assay allowed us to monitor the contribution of RNAP II
transcriptional activity to transcript levels independent of the
effect of RNA stability [70]. To do this, HFF cells were infected
with ADddUL79 in the presence or absence of Shld1 and the
nuclei of infected cells were isolated at 24 hpi (early timepoint)
or 72 hpi (late timepoint) and analyzed by NRO assay. The
amounts of newly synthesized run-on RNA were measured by
quantitative reverse transcription-coupled quantitative PCR
(RT-qPCR) analysis using primers specific to the promoter or
transcript regions of viral genes or cellular genes (Fig. 6A and
Table S2). Additionally, total RNA was also harvested to
monitor the total transcript accumulation.
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We found that in the absence of pUL79, the run-on RNA levels
of both MIE and late genes (UL99 and UL32) were reduced at late
times of infection (72 hpi) to approximately 40% of those in the
presence of pUL79 (Figs. 6B–6C). The run-on RNA levels of early
genes (UL44 and UL54) without pUL79 were also reduced to
approximately 60% of those with pUL79 (Fig. 6C). As RNAP II
transcribes at the rate of 1.3–4.0 kb/minute [71], our NRO assay
was performed for 30 minutes, which is long enough for RNAP II
to transcribe all the viral genes tested. However, without pUL79,
RNAP II still failed to transcribe viral genes at the levels
comparable to those in pUL79-containing controls at late times
of viral infection. We have observed more RNAP II on viral loci in
the absence of pUL79 during late stages of viral infection (Figs. 4–
5). If these RNAP II complexes functioned properly, we would
expect more RNA transcripts to be made in a NRO assay that
specifically measured the transcriptional elongation rate. However,
we instead found that the RNAP II elongation rate was reduced on
viral loci in the absence of pUL79. This is consistent with the
hypothesis that the slow-moving RNAP II complexes jammed
along viral loci, resulting in its excessive accumulation on viral
DNA. Finally, the run-on transcript levels of early genes were
indistinguishable at early times of viral infection (i.e. 24 hpi) with
Figure 2. pUL79 interacts with the RNAP II protein complex. In (A–B), HFFs were infected as described in Fig. 1, and at 72 hpi cell lysates were
immunoprecipitated using either an anti-FLAG antibody (A) or anti-Rpb1 antibody N-20 (B). Immunoprecipitated proteins and lysate inputs were
analyzed by immunoblotting. To examine the efficiency of nuclease digestion, the immunoprecipitated samples were also analyzed on an ethidium
bromide (EtBr)-stained agarose gel. In (C–D), nuclear lysates from HEK-293T cells transiently expressing HA-tagged pUL79 or empty vector control
were prepared at 72 hours post transfection. Lysates were immunoprecipitated using either an anti-HA antibody (C) or anti-Rpb1 antibody 8WG16
(D). Immunoprecipitated proteins and lysate inputs were analyzed by immunoblotting. The clone names of antibodies used in immunoblot analysis
are shown. Representative results from three independent experiments are presented.
doi:10.1371/journal.ppat.1004350.g002
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or without pUL79 (Fig. 6C). Therefore, we conclude that pUL79
is required for the RNAP II elongation on viral loci at late times of
viral infection.
As a control, we also examined the run-on RNA levels of host
genes GAPDH, RPL30 (which encodes a 60S ribosomal protein),
and MxA (which is a human interferon stimulated gene). Both
GAPDH and RPL30 possess a pattern of histone modifications
typical of permissive chromatin, similar to those associated with
most CMV viral loci during late times of infection [72]. MxA does
not encode a TATA box in its promoter [73] and its transcription
is suppressed during HCMV infection [74]. In contrast to viral
genes, neither the run-on RNA levels nor total RNA accumula-
tions of three host genes were altered by pUL79 at early or late
times of viral infection (Fig. 6D). This is consistent with the ChIP
analysis in that the occupancy of RNAP II at GAPDH was found
unaltered in the absence of pUL79 (Fig. 4B), and indicates that
RNAP II does not stall at host genomic loci even without pUL79.
Therefore, pUL79 is specifically required for efficient transcription
of viral genes but not host genes.
The HCMV genome is dense and many viral regions are
transcribed in both directions, resulting in multiple overlapping or
co-terminal transcripts. Therefore, the result of analyzing only one
viral locus may be complicated by the presence of overlapping
transcripts from neighboring genes. We therefore also examined
the RNAP II occupancy and elongation rate at multiple loci of
UL48 (Fig. 7A), the longest HCMV gene with late kinetics and
where RNAP II occupancy has been characterized in a previous
study [75]. Similar to other late viral genes that we examined in
this study, RNAP II occupancy on all three loci of the UL48
region examined was increased in the absence of pUL79 (Fig. 7B).
Without pUL79, RNAP II accumulated excessively throughout
the UL48 transcribed region, in proportion to its CTD phosphor-
ylations (Figs. 7C–D). However, UL48 transcripts failed to
accumulate efficiently in the absence of pUL79 at late times of
viral infection (Fig. 7E). Consistently, at late times of infection
RNAP II elongation was reduced on all three UL48 loci in the
absence of pUL79, even though the reduction in elongation rates
appeared to vary among different UL48 loci (Fig. 7F).
Taken together, our results from the NRO assay provide
definitive evidence that pUL79 positively regulates the transcrip-
tion rates of viral genes but not those of host genes. In the absence
of pUL79, RNAP II may still elongate at viral loci but does so at a
much slower pace at late times of infection, and ultimately fails to
support productive viral gene transcription and viral progeny
production.
Discussion
In this study, we discovered a novel regulatory mechanism of
viral transcription mediated by HCMV protein pUL79. We
identified cellular RNA polymerase II (RNAP II) as a key factor
that interacted with pUL79. This interaction did not alter the
overall accumulation of total RNAP II or its various phospho-
isoforms during viral infection. Rather, our data suggest that this
interaction allowed pUL79 to act as a virus-encoded elongation
factor to stimulate transcriptional elongation activity of RNAP II
on viral loci during late stages of viral infection where pUL79 is
expressed. Without pUL79, RNAP II elongation failed to proceed
efficiently and stalled on the viral genome. This caused slow
turnover and excessive amounts of RNAP II accumulation on viral
loci. Ultimately, this led to the failure of productive viral late
transcription and progeny production.
Why is pUL79 only required for viral transcription at late
times but not at early times during infection, even though
pUL79-mediated regulation occurs at viral loci of all three kinetic
classes (immediate-early, early, and late) (Fig. 6)? pUL79 is a late
protein and is not expressed until late times of infection. We and
others have shown that immediate-early and early genes are
transcribed efficiently at early times before pUL79 is expressed
(Fig. 6) [42,43]. It is possible that some transcripts made at early
times are stable and persist to late times of infection. When overall
transcript accumulations were analyzed, the presence of these pre-
existing transcripts could render it difficult to reveal the effect of
pUL79 on transcription of immediate-early and early genes at late
times during infection. However, the NRO assay measures relative
transcription elongation rates at specific gene loci at defined times
post infection, and is not affected by pre-existing transcripts.
Therefore, it reveals more viral genes than previously expected
where pUL79 drives the transcription during late times of viral
infection. A more systematic NRO analysis, such as global run-on
sequencing (GRO-seq) of virally infected cells, will further define
the scope of viral transcription regulated by pUL79.
Many viral factors have been shown to enhance transcription
subsequent to initiation through diverse mechanisms. HIV Tat
binds to host positive transcription elongation factor (P-TEFb) to
remove the blockage of transcription elongation imposed by NELF
and DSIF. The Tat/P-TEFb complex stimulates elongation and
Figure 3. pUL79 does not alter protein accumulations of RNAP
II. HFFs were infected with ADddUL79 at an MOI of 3 in the presence or
absence of 1 mM Shield-1 (Shld1). Cells were harvested at different
times post infection and protein accumulation was analyzed by
immunoblot analysis with antibodies recognizing various subunits
and isoforms of RNAP II, cellular CTD kinases (cyclin T1, CDK9), or viral
proteins (immediate-early protein IE1, early-late protein pUL44, late
protein pp71). The protein accumulation of the ddFKBP tagged pUL79
was monitored by an antibody recognizing the FKBP-epitope.
Representative results from three independent experiments are shown.
doi:10.1371/journal.ppat.1004350.g003
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co-transcriptional processing of proviral transcripts (Reviewed in
[76]). During human adenovirus (HAdV) infection, viral protein
E1A recruits hPaf1 complex to enhance transcriptional elongation
of viral early genes [77]. In herpesviruses, HSV-1 ICP27 interacts
with RNAP II CTD to recruit the RNAP II complex to viral
promoters [78]. HSV-1 ICP22 binds cdk9 to reduce the serine-2
phosphorylated CTD form of RNAP II [79–81]. Together, they
regulate the recruitment and proteasome-dependent degradation
of RNAP II complex during infection to facilitate viral gene
transcription. However, during HCMV infection, RNAP II
complex does not undergo extensive protein degradation. In
contrast, various isoforms of RNAP II, including the serine-2
phosphorylated CTD form, accumulate as viral infection pro-
gresses (Fig. 3). pUL79 does not alter either RNAP II protein
accumulation (Fig. 3) or enhance RNAP II recruitment (Fig. 4).
Therefore, pUL79 uses a mechanism distinct from other known
viral transcriptional elongation regulators to facilitate RNAP II
elongation.
Recently, human elongin B was shown to increase the efficiency
of RNAP II elongation on viral loci [75]. The siRNA knockdown
of elongin B decreases viral mRNA expression as well as reduces
RNAP II protein accumulation and occupancy of its serine-2
phosphorylated form on viral loci [75]. Interestingly, elongin B is
required for viral mRNA expression of various kinetic classes
throughout the whole infection cycle. In contrast, pUL79 is only
required at late stages of infection and does not appear to alter the
occupancy of various CTD phospho-isoforms of RNAP II on viral
loci (Fig. 5). Whether pUL79 interacts with host elongation factors
such as elongin B to exert its activity, or how pUL79 selectively
modulates the transcription elongation complex at late times of
infection, requires further exploration.
What is the potential mechanism for pUL79 to modulate the
elongation rate of RNAP II? It is possible that pUL79 enhances
promoter clearance, a step in which RNAP II transfers from the
initiation state to the elongation state (Fig. 8A). During the
transcription cycle, RNAP II is recruited to promoters by cellular
TATA-box binding protein (TBP) and other general transcription
factors (GTFs) to form the pre-initiation complexes (PIC). The
PIC places RNAP II at transcription start sites, denatures DNA,
and positions DNA into the RNAP II active site for transcription
[82]. Once transcription initiates, RNAP II dissociates from the
PIC and recruits elongation factors for efficient transcription. The
dissociation of RNAP II from the PIC is mediated by TFIIH and
other cellular kinases to facilitate exchange between initiation
factors and elongation factors [83,84]. Inefficient dissociation from
PIC reduces the rate of RNAP II elongation, resulting in the
Figure 4. pUL79 alters RNAP II occupancy at viral loci. (A) Schematic representation of the HCMV genes and host GAPDH gene examined by
chromatin immunoprecipitation assay (ChIP). Locations and sizes of primer-probe pairs used in ChIP-qPCR analysis are indicated. (B) HFF cells were
infected with ADddUL79 at an MOI of 3 in the presence or absence of 1 mM Shld1. Cell extracts were prepared at 72 hpi and analyzed by ChIP assay
using rabbit an anti-RNAP II antibody N-20. Normal rabbit IgG was included as a control for non-specific immunoprecipitation. Amounts of input and
precipitated (output) DNAs were quantified by qPCR with primers specific for indicated viral loci or human GAPDH. The output-to-input DNA ratios
were determined from four independent ChIP experiments with standard deviations calculated by Prism 6 software. Statistical analysis was
performed using Student’s t test (**, P,0.01; ***, P,0.005; ****, P,0.0001; NS, not significant). (C) HFF cells were infected with ADflagUL79 or ADwt
at an MOI of 3. Cell extracts were prepared at 72 hpi and analyzed by ChIP assay using anti-FLAG antibody. Normal mouse IgG was included as a
control. Amount of input and precipitated (output) DNAs were quantified by qPCR with primers used in (B). The output-to-input DNA ratios were
determined from three independent ChIP experiments with standard deviations calculated by Prism 6 software. Statistical analysis was performed
using Student’s t test (*, P,0.05; **, P,0.01).
doi:10.1371/journal.ppat.1004350.g004
CMV pUL79 Is a Viral Elongation Factor of RNAP II
PLOS Pathogens | www.plospathogens.org 9 August 2014 | Volume 10 | Issue 8 | e1004350
failure to transcribe genes [83]. Several herpesviral proteins have
been reported to act as viral transcription initiation factors to form
a unique viral PIC. For example, the homologues of HCMV
UL87 in gamma-herpesviruses were reported to encode viral TBPs
and regulate late transcript accumulation [23,50]. However, in
general TBP loads onto the promoter independent of other factors,
and this is consistent with the observation that EBV BcRF1
(homologue of HCMV pUL87) binds to the viral promoter
independent of any other partners [50]. Because of this and also
the observation that the total RNAP II accumulation on viral loci
is not reduced in the absence of pUL79 (Fig. 4B), we hypothesize
that pUL79 is not required for the recruitment of pUL87 or
subsequently RNAP II to viral promoters. MHV68 ORF30 and
ORF34, homologues of HCMV UL91 and UL95, are shown to be
required for RNAP II recruitment to viral late promoters [48].
However, RNAP II recruitment to viral promoters is not reduced
in the absence pUL79, suggesting that pUL79 is not required for
this putative activity of pUL95 (Fig. 4B). Together, we hypothesize
that pUL79 is not required for transcription initiation (Fig. 4B).
However, the elongation rate of RNAP II at viral loci is reduced
Figure 5. pUL79 does not alter a particular phosphorylated form of the RNAP II CTD domain. HFF cells were infected with ADddUL79 at
an MOI of 3 in the presence or absence of 1 mM Shld1. Cell extracts were harvested at 72 hpi and analyzed by ChIP assays. Rabbit antibody to pSer2
CTD, rat antibody to pSer5-CTD, and mouse antibody to non-phosphorylated CTD (8WG16) were used in ChIP assays. Normal rabbit, rat, and mouse
IgGs were included as controls for non-specific precipitation, respectively. Immunoprecipitated DNAs were analyzed as described in Fig. 4B and the
output-to-input DNA ratios are presented in (A). In addition, the immunoprecipitated amount of each phosphor-isoform of RNAP II CTD relative to
that of total RNAP II (immunoprecipitated with antibody N-20) was also calculated and presented in (B). Data from four independent experiments
were collected with standard deviations calculated by Prism 6 software. Statistical analysis was performed using Student’s t test (*, P,0.05; **, P,
0.01; ***, P,0.005).
doi:10.1371/journal.ppat.1004350.g005
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drastically, suggesting that pUL79 is essential for a transcription
step downstream of initiation (Fig. 6). Strikingly, pUL79 co-
purifies with pUL87 and pUL95, two viral factors potentially
involved in viral PIC assembly (Table 1). Therefore, even though
pUL79 is unlikely to facilitate pUL87 and pUL95 to mediate viral
PIC assembly, it is intriguing to speculate that pUL79 may
regulate the activity of pUL87 and pUL95 downstream of
transcription initiation. As the viral PIC complex may not be
recognized by host dissociation factors, it is possible that pUL79
plays a role in the release of RNAP II from viral PIC prior to
elongation (Fig. 8A). To test this, further analysis is required to
determine the composition of RNAP II/viral PIC as well as their
distribution on the viral DNA.
It is also possible that pUL79 plays a role in epigenetic
regulation to modulate viral transcription (Fig. 8B). During
HCMV infection, viral DNA is chromatinized and undergoes
histone modifications to facilitate gene expression [85]. In
particular, upon the onset of viral DNA replication, newly
synthesized viral DNA is wrapped with histone 3 with lysine 4
methylation (H3K4me2), a modification that favors active
transcription, suggesting the potential involvement of epigenetic
regulation in viral late transcription [72]. Even though pUL79 was
not required for methylating H3K4 [72], the possibility remains
that pUL79 may act as an epigenetic reader to recognize histone
modifications unique to viral DNA, and unwrap viral DNA
packaged by histones to facilitate RNAP II elongation (Fig. 8B).
How does pUL79 specifically regulate transcription of viral loci?
In this study, we showed that pUL79-mediated transcriptional
regulation was limited to viral genes, but not host genes (i.e.
GAPDH, RPL30, and MxA). This specificity may be partially due
to the localization of pUL79 during infection as pUL79 is enriched
in viral replication compartments where late viral transcription
occurs [42]. In addition, late promoters of beta- and gamma-
herpesviruses contain a non-canonical TATA box sequence [50].
EBV BcRF1, the homologue of HCMV pUL87, is a viral TATA-
box binding protein which preferentially binds to this non-
canonical TATA box over the canonical sequence. This suggests
that viral transcription machinery directs RNAP II to viral late
promoters during late stages of viral infection [50]. In HCMV,
several characterized viral late promoters also contain the same
non-canonical TATA sequences [86–91]. Therefore, pUL79 may
also act as a viral specific TATA-box binding protein. However, in
this study we observed an overall decrease in transcription rates
among all three kinetic classes of viral loci during late times of
infection (Fig. 6). Further analysis is needed to understand how
pUL79 can regulate the rate of viral transcription regardless of the
structures of gene promoters.
In this study, we found that pUL79 also co-purified with other
viral regulators of HCMV late gene expression, suggesting that
pUL79 may interact with these regulators to form complexes
during viral infection (Table 1). It is not known whether these viral
regulators use similar mechanisms to regulate viral transcription.
For example, pUL91 and pUL92 were shown to specifically
regulate only true late genes [41]. It is possible that these
regulators have conserved functions and yet still possess different
specificities. In addition, pUL79 also co-purified with viral DNA
replication factors (Table 1). Previously, we have shown that
pUL79-mediated viral transcription requires the onset of viral
DNA synthesis [42]. Expression of neither pUL79 alone nor the
combination of all known late gene regulators alters the expression
kinetics of viral genes, especially viral late genes [41,42].
Therefore, it is also possible that viral DNA synthesis events
predispose viral DNA to late transcription via interactions between
replication factors and pUL79.
In conclusion, we have used a systematic proteomic approach to
elucidate the mechanism underlying the activity of the HCMV late
gene expression regulator pUL79. pUL79 interacts with RNAP II
to modulate its transcription rate at viral loci during late times of
viral infection. This unique viral mechanism is potentially
conserved among beta- and gamma- herpesviruses, and provides




pYD-C755 (i.e. pLKO) was a pLKO-based lentiviral vector
(also referred as pLKO.DCMV.TetO.mcs in [92], a generous gift
from Roger Everett, University of Glasgow Centre for Viral
Research). pYD-C751 (i.e. pLKO-HA-pUL79) was created by
cloning a PCR fragment containing the UL79 coding sequence
along with an N-terminal hemagglutinin (HA) tag into the multiple
cloning site of pYD-C755. pYD-C744 was derived from pGalK
[93], and carried a cassette in which 36FLAG tag was followed by
a GalK/kanamycin dual expression cassette flanked by the Flp
recognition target (FRT) sequence [94].
The synthetic chemical ligand Shield-1 (Shld1) used to regulate
the stability of ddFKBP-tagged proteins was purchased from
Cheminpharma (Farmington, CT). Benzonase was purchased
from EMD Millipore. The following primary antibodies were used
in this study: anti-beta actin (clone AC15, Abcam); anti-FLAG
(clone M2/F1804 and M2/F3165, Sigma-Aldrich); anti-HA (clone
16B12, Covance; clone 3F10, Roche); anti FKBP12 (clone 8/
FKBP12, BD Biosciences); anti-Rpb1 (clone N-20 from Santa
Cruz to detect total Rpb1; or clone 8WG16 from Abcam to detect
both total Rpb1 and the unphosphorylated CTD form of Rbp1);
anti-Rpb2 (S-20, Santa Cruz); anti-Rpb1 phospho-CTD Ser5/
Ser2 (clone H-14, Covance); anti-Rpb1 phospho-CTD Ser5 (clone
3E8, Millipore); anti-Rpb1 phospho-CTD Ser2 (ab5095, Abcam);
anti-CDK9 (clone H-169, Santa Cruz); anti-cyclin T1 (clone H-
245, Santa Cruz); anti-pUL44 (clone 10D8, Virusys); anti-IE1,
anti-pp28, and anti-pp71 (generous gifts from Thomas Shenk,
Princeton University).
Cells and viruses
Primary human newborn foreskin fibroblasts (HFFs) and HEK-
293T cells were propagated in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% fetal calf serum, nonessential
amino acids, sodium pyruvate, and penicillin-streptomycin.
Three HCMV recombinant viruses, ADwt, ADddUL79, and
ADflagUL79, were used in this study. The wildtype virus ADwt
was reconstituted from the BAC-HCMV clone pADwt (also
referred as pAD-GFP in the previous study [42]). pADwt carries
the full-length genome of HCMV strain AD169, with the
exception that it contains a simian virus 40 (SV40) early
promoter-driven green fluorescent protein (GFP) gene in place
of the viral US4–US6 region that is dispensable for viral
replication in HFFs [95,96]. ADddUL79 was derived from ADwt
using BAC recombineering, where the pUL79 coding sequence
was fused to that of destabilizing domain ddFKBP [42].
ADflagUL79 was reconstituted from the BAC clone pAD-
flagUL79. This BAC clone was derived from pADwt, and was
constructed by using a linear recombination approach in the
bacterial strain SW105 that contained an arabinose-inducible Flp
gene for the transient expression of Flp recombinase [94]. Briefly,
the cassette that carried 36FLAG followed by the GalK/
kanamycin dual marker was first generated by PCR from pYD-
C744 with a pair of 70-bp primers, so that the PCR-generated
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cassette was also flanked by 50-bp viral sequences immediately
upstream or downstream of the 59-end of the UL79 coding
sequence. The cassette was recombined into pADwt at the 59-end
of the UL79 coding sequence by using linear recombination. The
GalK/kanamycin marker was subsequently removed by Flp-FRT
recombination [94]. The final clone pADflagUL79 contained the
36FLAG sequence along with a small FRT site fused in frame at
the 59-terminus of the UL79 coding sequence (Fig. 1A).
To reconstitute virus, 2 mg of the BAC-HCMV DNA and 1 mg
of the pp71 expression plasmid were transfected into HFF cells by
electroporation [96], and the culture medium was changed
24 hours later. For reconstitution of ADddUL79 virus, Shld1
was added every 48 hours to maintain the concentration at 1 mM.
Reconstituted virus was harvested by collecting cell-free culture
supernatant when the entire monolayer of cells was lysed. To
produce virus stocks, cell-free culture supernatants were collected
from HFFs infected at an MOI of 0.01. Viruses were pelleted by
ultracentrifugation through a 20% D-sorbitol cushion at an
average relative centrifugal force of 53,0006g for 1 hour,
resuspended in DMEM with 10% tissue fetal calf serum, and
saved as viral stocks. HCMV titers were determined by 50%
culture infectious dose (TCID50) assay in HFFs [42].
Transient transfection
Four mg of plasmid DNA and 12 ml polyethylenimine (PEI)
(1 mg/ml, Polysciences) were mixed with 100 ml OPTI-MEM
(Invitrogen) and incubated at room temperature for 10 minutes.
The mixture was then added to 900 ml complete medium
containing 10% fetal calf serum, and applied to 56106 HEK-
293T cells that were seeded one day before. Cells were incubated
for 4 hours before medium was changed.
Analysis of immunoprecipitation, mass spectrometry,
and immunoblotting
For total cell lysates, immunoprecipitation was performed using
a protocol modified from previous studies [67,97,98]. In brief,
HFF cells (56107) were infected with HCMV ADflagUL79 or
ADwt at a multiplicity of infection (MOI) of 3. At 72 hpi, cells
were collected, rinsed twice with cold phosphate-buffered saline
(PBS), and lysed in 2 ml EBC2 buffer (50 mM Tris [pH 8.0],
300 mM NaCl, 0.5% NP40) supplemented with protease and
phosphatase inhibitors. Cell lysates were then supplemented with
250 unit (U) Benzonase nuclease (Millipore), incubated at 4uC for
15 minutes. One aliquot of cell lysates was saved as the input
control and boiled in the LDS sample buffer in the presence of
sample reducing agent (Novex). The remainder was clarified by
centrifugation at 10,0006g at 4uC for 15 minutes. The superna-
tant was incubated with protein A-dynabeads (Novex) conjugated
with antibody to FLAG (M2) or Rpb1 (N-20) together with an
additional 250 U of Benzonase at 4uC overnight. In addition, to
confirm the nuclease activity of Benzonase, an aliquot of the
supernatant was analyzed on a 0.8% agarose gel containing
100 mg/ml ethidium bromide for the detection of DNA/RNA.
The following day the beads were washed three times with 1 ml
EBC2 buffer and once with EBC2 buffer without NP40. The
immuneprecipitants were eluted by boiling in reducing sample
buffer for 5 minutes. For nuclear extracts, immunoprecipitation
was performed using the Nuclear Complex Co-IP kit according to
the manufacturer’s instructions (Active Motif).
For mass spectrometry analysis, cell lysates were prepared in the
presence of Benzonase (250 U per 56107 HFF cells), and the
efficiency of enzyme digestion was examined in ethidium bromide-
stained agarose gel electrophoresis analysis (Fig. S2). Proteins
precipitated by anti-FLAG antibody were resolved on a NuPAGE
4–12% gradient gel (Novex) and subsequently stained using a
ProteoSilver Silver Stain kit (Sigma-Aldrich) according to the
manufacturer’s instruction. Protein bands unique to ADflagUL79-
infected sample were extracted. In addition, gel bands from the
ADwt-infected sample with migrating positions corresponding to
those of ADflagUL79-specific bands were also extracted as
negative controls. Extracted gel samples were submitted to the
Keck Mass Spectrometry and Proteomics Facility (School of
Medicine, Yale University) for liquid chromatography (LC)-mass
spectrometry analysis for protein identification.
Protein amounts were determined by immunoblot analysis as
previously described [42]. In brief, proteins were resolved on an
SDS polyacrylamide gel, transferred to a polyvinylidene difluoride
(PVDF) membrane, hybridized with a primary antibody, reacted
with the horseradish peroxidase-conjugated secondary antibody,
and visualized using chemiluminescent substrate (Thermo Scien-
tific).
Chromatin immunoprecipitation (ChIP)
The ChIP was performed using the MAGnify chromatin-
immunoprecipitation system (Life Technologies) and reagents
provided in the kit according to the manufacturer’s protocol with
modifications. To prepare the chromatin lysates of ADddUL79
infected cells, 26106 HFFs were infected with ADddUL79 at an
MOI of 3.0 in the presence or absence of Shld1. To prepare the
chromatin lysates of ADflagUL79 or ADwt infected cells, 26106
HFFs were infected with ADflagUL79 or ADwt viruses without
Shld1. At 72 hours, infected cells were washed twice with PBS,
trypsinized, and crosslinked with 1% formaldehyde at room
temperature with mixing for 10 minutes. Glycine was added to the
final concentration of 125 mM and incubated at room temper-
ature for 5 minutes to stop the cross-linking reaction. Cells were
collected by centrifugation at 4uC, 2006g for 10 minutes, washed
twice in ice-cold PBS, and lysed in 100 ml lysis buffer with protease
inhibitors. Chromatins were sheared into 200–500 bp fragments
using either a cup-horn Branson Sonifier 450 (30-second pulse and
60% output with 40-second interval for 70 times in ice water) or a
NGS Bioruptor (Diagenode) (3610 cycles of 15-seconds on/45-
seconds off in a automatic water cooling system). Samples were
gently vortexed every five sonication cycles and allowed to cool in
ice water for an additional 2 minutes. Lysates were cleared by
Figure 6. pUL79 alters the rate of transcriptional elongation at viral loci. (A) Schematic representation of the HCMV genes and host genes
examined by the nuclear run-on (NRO) assay. Locations and sizes of primer-probe pairs used in subsequent RT-qPCR analysis are indicated. (B–D)
HFFs were infected with ADddUL79 at an MOI of 3 in the presence or absence of 1 mM Shld1 (indicated by ‘‘+’’ or ‘‘2’’ sign, respectively). Nuclear
extracts were prepared at 24 or 72 hpi and analyzed by NRO assays. Transcription elongation was allowed to resume for 30 minutes in the presence
of biotin-labeled UTP, labeled RNA was isolated, and their amounts were determined by RT-qPCR. In addition, accumulations of total RNAs were also
determined by RT-qPCR. The normalized amounts of viral run-on transcripts or total transcripts in the presence of Shld1 were set at 1 for the NRO
assay or total transcript accumulation analysis, respectively. (B) Relative amounts of total and run-on transcripts of viral late genes UL99 and UL32. (C)
Relative amounts of run-on and total transcripts of viral immediate-early and early genes. (D) Relative amounts of run-on and total transcripts of host
genes. Data from three independent experiments were collected and standard deviations were calculated by Prism 6 software. Statistical analysis was
performed using Student’s t test (**, P,0.01; ***, P,0.005; NS, not significant).
doi:10.1371/journal.ppat.1004350.g006
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centrifugation (20,0006g, 15 minutes; 4uC) and stored as 20-ml
aliquots. To confirm the size of sheared chromatin fragments, one
20-ml aliquot was treated with RNase A at 37uC for 1 hour and de-
crosslinked by protease K treatment overnight. DNA was purified
and analyzed by agarose gel electrophoresis (data not shown).
To immunoprecipitate protein-bound chromatin fragments,
each 20-ml aliquot was diluted in dilution buffer with protease
inhibitors, and first incubated with 40 ml BSA-preblocked protein
A/G Dynabeads to pre-clean for 2 hours. Beads were removed,
and one tenth volume of the supernatant was saved as the input
sample. The remainder of the supernatant was incubated with
appropriate antibodies to generate protein-antibody complexes or
with IgG (negative control) (Table S1) at 4uC for 16 hours. Forty
ml BSA-preblocked protein A/G Dynabeads (Invitrogen) was
added to the samples and incubated at 4uC for another 1.5 hours
to immunoprecipitate the complexes. Beads were collected,
washed twice with IP Buffer 1 and three times with IP Buffer 2.
Protein-antibody complexes were eluted from Dynabeads by
incubation with reverse crosslinking buffer with proteinase K at
55uC for 15 minutes. Dynabeads were removed, and crosslinking
of protein-antibody complexes in the supernatant were reversed by
incubation at 65uC for 15 minutes. In addition, the input sample
was also treated with the reverse crosslinking buffer in the same
procedure to reverse crosslinking. Both input and immunoprecip-
itated DNAs were isolated by DNA purification on magnetic
beads. DNA fragments were quantified by quantitative PCR
Figure 7. pUL79 alters the rate of transcriptional elongation at various regions of the UL48 gene. (A) Schematic representation of the
HCMV gene UL48. Primer-probe pairs used for analysis are indicated. (B–D) HFF cells were infected with ADddUL79 at an MOI of 3 in the presence or
absence of 1 mM Shld1. Cell extracts were harvested at 72 hpi and analyzed by ChIP assays as described in Fig. 4 and Fig. 5. (B) represents the output-
to-input DNA ratios of RNAP II ChIP. (C) represents the output-to-input DNA ratios of pSer5-CTD, pSer2-CTD, and non-phosphorylated CTD ChIPs. (D)
represents the immunoprecipitated amount of each phosphor-isoform of RNAP II CTD relative to that of total RNAP II (immunoprecipitated with
antibody N-20). Data from four independent experiments were collected with standard deviations calculated by Prism 6 software. (E–F) HFFs were
infected with ADddUL79 at an MOI of 3 in the presence or absence of 1 mM Shld1 (indicated by ‘‘pUL79+’’ or ‘‘pUL792’’, respectively). Nuclear extracts
were prepared at 72 hpi and analyzed by NRO assay as described in Fig. 6. Relative amounts of total transcripts and run-on are presented in (E) and
(F), respectively. Statistical analysis was performed using Student’s t test (*, P,0.05; **, P,0.01; ***, P,0.005).
doi:10.1371/journal.ppat.1004350.g007
Figure 8. Potential role of pUL79 in RNAP II-mediated viral transcription. During late times of viral infection where pUL79 is expressed, we
propose two models where pUL79 may act as an elongation factor to facilitate viral transcription. (A) In the ‘‘promoter clearance’’ model, pUL87,
pUL92, pUL95, and potentially other viral factors (shown as red dashed circles) form viral protein pre-initiation complexes (vPIC) to recruit RNAP II to
viral promoters. Once transcription initiates, pUL79 interacts with the vPIC to release RNAP II from the vPIC for efficient elongation. In the absence of
pUL79, RNAP II is unable to dissociate from vPIC and fails to recruit elongation factors for continued transcription. (B) In the ‘‘epigenetic reader’’
model, pUL79 acts as an epigenetic reader to recognize chromatin modification(s) to facilitate RNAP II elongation. During late times of infection,
newly synthesized viral DNA is wrapped with specific histone modifications (shown as purple dashed ovals). pUL79 recognizes these modifications,
and then dissociates viral DNA from chromatin binding, with or without other cellular/viral factors, to facilitate RNAP II elongation. In the absence of
pUL79, RNAP II is unable to pass through the unopened chromatin, resulting in transcriptional stalling on viral loci.
doi:10.1371/journal.ppat.1004350.g008
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(qPCR) using SYBR Select Mix (Invitrogen) kit or Taqman Fast
Advanced Master Mix kit (Invitrogen). The sequences of primers
and Taqman probes are listed in Table S2.
Nuclear run-on (NRO) assay
The protocol of the NRO assay was adapted from previous
studies with modifications [70,99,100]. 16107 HFFs were infected
with ADddUL79 at an MOI of 3 in the presence or absence of
Shld1. At 72 hpi, cells were washed twice with PBS, trypsinized,
collected by centrifugation (4uC, 2706g), and washed twice with
cold PBS again to remove residual calcium and magnesium. To
extract nuclei, cell pellets were resuspended in 4 mL cell lysis
buffer (10 mM Tris-HCl, pH 7.2, 3 mM MgCl2, 10 mM NaCl,
150 mM sucrose, and 0.5% NP40) for 5 minutes on ice. Extracted
nuclei were collected by centrifugation (4uC, 1706g) and gently
washed with cell lysis buffer to remove NP40. Pellets were
resuspended in 300 ml freezing buffer (50 mM Tris-HCl, pH 8.3,
40% glycerol, 5 mM MgCl2, and 0.1 mM EDTA), washed once
with 16 run-on reaction buffer (20 mM Tris-HCl, pH 7.5,
10 mM MgCl2, 150 mM KCl, and 20% (v/v) glycerol). To
perform NRO assay, 107 nuclei were incubated in 100 ml 16run-
on reaction buffer with ATP, CTP, GTP (0.5 mM each), and
0.2 mM biotin-16-UTP (Invitrogen) at 29uC for 30 minutes. The
reaction was stopped by snap freezing in liquid nitrogen. As
negative controls, run-on reactions were also performed with UTP
instead of biotin-16-UTP. To isolate biotin-labeled run-on
transcripts, streptavidin-coated Dynabeads (Dynabeads MyOne
Streptavidin C1, Invitrogen) were resuspended in binding buffer
(10 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 2 M NaCl), and
mixed with an equal volume of run-on transcripts. The samples
were incubated at 42uC for 20 minutes and then at room
temperature for 1.5 hours. Beads were collected, and washed
twice with 15% formamide and three times with 26 standard
saline citrate (Invitrogen). Biotinylated RNAs on the beads were
reverse transcribed to generate cDNA using SuperScript VILO
cDNA Synthesis Kit (Invitrogen), and quantified by reverse
transcription-coupled qPCR (RT-qPCR) analysis. The relative
transcript amounts were normalized to those of 18S rRNA (that is
transcribed by RNA polymerase I (RNAP I) so is an unbiased
internal control for RNAP II activity). In addition, total RNA of
infected cells was also isolated separately by TRIzol extraction
(Invitrogen) and the amounts were determined by RT-qPCR
analysis (see Table S2 for primer sequences).
Supporting Information
Figure S1 Accumulation of ddFKBP tagged pUL79 is
regulated by Shld1 during infection. HFFs were infected
with ADddUL79 at an MOI of 3 in the presence or absence of
1 mM Shld1. Nuclear extracts were prepared from infected cells at
different times post infection, and protein accumulation of the
ddFKBP tagged pUL79 was monitored by an antibody recogniz-
ing the FKBP-epitope. Viral immediate-early protein IE1 and host
protein actin were used as infection and loading controls,
respectively, and detected by immunoblotting with respective
antibodies. Representative results from three independent exper-
iments are shown.
(TIF)
Figure S2 Nuclease digestion of immunoprecipitated
samples from infected cell lysates for mass spectrom-
etry analysis. To prepare samples for mass spectrometry
analysis as depicted in Fig. 1D, cell lysates were treated with or
without Benzonase (250 U per 56107 HFF cells) and the efficiency
of enzyme digestion was examined on an ethidium bromide
(EtBr)-stained agarose gel. Only Benzonase-treated samples were
processed for subsequent mass spectrometry to identify pUL79
protein partners.
(TIF)
Figure S3 pUL79 is associated with viral loci during
HCMV infection. The data in Fig. 4C are re-graphed with the
y-axis scales of the output-to-input DNA ratio proper for each
sample set. This allows visualization of the difference between the
FLAG-pUL79 samples relative to the untagged pUL79 controls.
(TIF)
Table S1 Antibodies used in chromatin immunoprecip-
itation assays.
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